Infectious complications associated with immunomodulating biologic agents

Sophia Koo; Francisco M Marty; Lindsey R Baden

doi:10.1016/j.idc.2010.01.006

Infectious complications associated with immunomodulating biologic agents

Infect Dis Clin North Am. 2010 Jun;24(2):285-306. doi: 10.1016/j.idc.2010.01.006.

Authors

Sophia Koo¹, Francisco M Marty, Lindsey R Baden

Affiliation

¹ Division of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, PBB-A4, Boston, MA 02115, USA. skoo@partners.org

PMID: 20466271
DOI: 10.1016/j.idc.2010.01.006

Abstract

The armamentarium of biologic therapies targeting specific elements of the immune system is rapidly expanding. This review describes the spectrum of infectious complications associated to date with each of the immunomodulating biologic therapies approved by the US Food and Drug Administration.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use*
Communicable Diseases / epidemiology*
Humans
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use*
United States

Substances

Antibodies, Monoclonal
Immunologic Factors